0000899243-22-022562.txt : 20220615
0000899243-22-022562.hdr.sgml : 20220615
20220615161535
ACCESSION NUMBER: 0000899243-22-022562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220613
FILED AS OF DATE: 20220615
DATE AS OF CHANGE: 20220615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SIDRANSKY DAVID
CENTRAL INDEX KEY: 0001277161
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39279
FILM NUMBER: 221017937
MAIL ADDRESS:
STREET 1: JOHNS HOPKINS UNIVERSITY
STREET 2: 720 RUTLAND AVENUE
CITY: BALTIMORE
STATE: MD
ZIP: 21205
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ayala Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001797336
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823578375
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1313 N. MARKET STREET
STREET 2: SUITE 5100
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: (857) 444-0553
MAIL ADDRESS:
STREET 1: 1313 N. MARKET STREET
STREET 2: SUITE 5100
CITY: WILMINGTON
STATE: DE
ZIP: 19801
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-13
0
0001797336
Ayala Pharmaceuticals, Inc.
AYLA
0001277161
SIDRANSKY DAVID
OPPENHEIMER 4
REHOVOT
L3
7670104
ISRAEL
1
0
0
0
Stock Option (Right to Buy)
1.63
2022-06-13
4
A
0
12500
0.00
A
2032-06-12
Common Stock
12500
12500
D
This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
/s/ Roni Mamluk, Ph.D., Attorney-in-Fact for David Sidransky
2022-06-15